Clinical Commander

Back to dossier
cardio.acute-hf.eosinophilic-myocarditis-decompensation.v1PRODUCTION
cardio.acute-hf.eosinophilic-myocarditis-decompensation.v1

Acute HF — eosinophilic myocarditis decompensation (non-shock)

cardiologyacuteadult
Hard-required inputs
0 / 12
Care setting:

Encounter flow

10/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Eosinophilic myocarditis ADHF (non-shock; SCAI A-B): peripheral eosinophilia + cardiac dysfunction + STEROID RESPONSIVE; identify etiology subset (drug/DRESS, parasitic, HES with FIP1L1-PDGFRA, EGPA, idiopathic) for targeted therapy in addition to steroids; standard ADHF supportive care; STRONGYLOIDES SCREEN before steroids; AVOID NSAIDs

Inputs
2
Actions
0
Advance rule
Set
Advance when

EM ADHF framed

Patient inputs (15)

Steroids precipitate Strongyloides hyperinfection syndrome (mortality >70%); MUST screen with serology + ivermectin empiric coverage if endemic exposure even pending result; AHA + IDSA recommendation

EM spans all ages; HES with FIP1L1-PDGFRA more common in middle-aged males; EGPA peaks 30-50 y; pediatric drug-induced cases route to peds-specific dossier

Drug timeline (2-8 wk pre-presentation typical for DRESS) + offending agent identification drives discontinuation as first therapeutic step; antibiotics, antipsychotics, anticonvulsants, allopurinol most common

EGPA classic triad: asthma + eosinophilia + vasculitis; cardiac involvement is leading cause of EGPA death; identifies need for cyclophosphamide/rituximab + steroids

Parasitic etiology (toxocara, schistosoma, strongyloides, trichinella) requires targeted antiparasitic; STRONGYLOIDES SCREEN MANDATORY before steroids (steroids precipitate fatal hyperinfection)

eGFR for diuretic + GDMT dosing (ARNI, MRA, SGLT2i thresholds); LFTs for congestive hepatopathy + DRESS hepatic involvement + drug-induced hepatitis screen

Cornerstone diagnostic — AEC >1500/µL supports EM (>5000 in HES classification); trend over days during steroid response (rapid drop within 48 h supports diagnosis)

Elevated in active EM (eosinophil-mediated myocyte injury); persistent elevation despite steroids portends worse outcome

HF severity marker; titrate diuresis; trend during admission for response monitoring

LV dysfunction (often regional + restrictive); MURAL THROMBUS very common in EM (endocardial damage prothrombotic) — apical or biventricular; pericardial effusion; serial echo for recovery

ECG abnormalities in 90%+ of EM (T-wave inversion, ST changes, AV block, low voltage from inflammation, pericardial pattern); persistent QRS prolongation portends worse prognosis

SBP <90 + lactate ≥2 + cool extremities → SCAI C+ shock → ROUTE to cardio.cardiogenic-shock.eosinophilic-myocarditis.v1; this engine handles SCAI A-B (warm + wet) only

FIP1L1-PDGFRA fusion (myeloid lineage HES) → IMATINIB curative response; mandatory in HES workup; identifies subset with dramatic targeted therapy response

p-ANCA / MPO-ANCA positive in 30-50% of EGPA; classification per ACR/EULAR 2022; drives cyclophosphamide/rituximab decision

Subendocardial LGE distribution classic for EM (vs mid-wall in viral, transmural in giant-cell); T2 edema mapping for active inflammation; native T1 for diffuse fibrosis; serial MRI at 3-6 mo for treatment response

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (6)

6 need judgement
  • informationallife_threateningprogression_to_fulminant_em_requiring_shock_pathway
    Hemodynamic deterioration to SCAI C+ shock (SBP <90 + lactate ≥2 + cool extremities + organ dysfunction) — fulminant EM requires MCS evaluation + emergent EMB
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningstrongyloides_exposure_with_planned_steroids_safety_failure
    Patient about to receive steroids without strongyloides screen completed AND endemic exposure history (Latin America, sub-Saharan Africa, SE Asia, immigration, travel) — life-threatening hyperinfection risk if not pre-treated
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningmural_thrombus_with_embolic_event
    Mural thrombus identified on echo (very common in EM — endocardial damage prothrombotic — Loeffler endocarditis) + systemic embolic event (stroke, peripheral arterial embolism, mesenteric, renal)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningsustained_vt_or_high_grade_av_block_during_active_em
    Sustained VT, VF, or high-grade AV block (Mobitz II, complete heart block) during active EM — proarrhythmic substrate from active eosinophilic infiltration
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveregdmt_intolerance_during_active_inflammation_phase
    Cannot tolerate GDMT initiation/up-titration due to hypotension, bradycardia, AKI, or hyperkalemia during active EM inflammation phase + ongoing immunosuppression
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereeosinophil_count_relapse_during_steroid_taper
    Rising peripheral eosinophil count (>1500/µL recurrence) during steroid taper with or without symptom recurrence — relapse of EM
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

Eosinophilic myocarditis ADHF (non-shock) — pulse methylprednisolone foundation + etiology-specific targeted therapy + standard ADHF + AC if mural thrombus + GDMT cautiously + MANDATORY strongyloides screen before steroids — ESC 2013 (PMID 23824828) + AHA 2020 (PMID 32200645) + Klion HES guidelines + MIRRA 2017 (PMID 28514601)
axis: eosinophilic_myocarditis_decompensation_phenotype
Selected axis "Eosinophilic myocarditis ADHF (non-shock) — pulse methylprednisolone foundation + etiology-specific targeted therapy + standard ADHF + AC if mural thrombus + GDMT cautiously + MANDATORY strongyloides screen before steroids — ESC 2013 (PMID 23824828) + AHA 2020 (PMID 32200645) + Klion HES guidelines + MIRRA 2017 (PMID 28514601)" by default fallback (first axis)
  • methylprednisolone
    first line
    glucocorticoid_iv_pulse
    1 g IV daily × 3-5 d (pulse) then prednisone 1 mg/kg/d PO taper over 6-12 mo • IV • daily × 3-5 d then PO taper
    triggers: eosinophilic_myocarditis_with_strongyloides_screen_complete_or_empiric_ivermectin_given
    CORNERSTONE — pulse methylprednisolone for active EM; dramatic response in 24-72 h in most cases; eosinophil count drops rapidly (supports diagnosis); prednisone taper guided by eosinophil count + clinical status; ESC 2013 (PMID 23824828) + AHA 2020 (PMID 32200645)
    rxcui 6902
  • prednisone
    first line
    glucocorticoid_oral
    1 mg/kg/d PO daily then taper by 10 mg q2wk to 20 mg then by 5 mg/mo to 5 mg then off; total 6-12 mo • PO • daily
    triggers: post_pulse_methylprednisolone_taper_phase
    Maintenance immunosuppression after pulse; titrated by eosinophil count + clinical response; prophylaxis against PCP (TMP-SMX) + steroid-induced osteoporosis (calcium + vit D ± bisphosphonate) standard
    rxcui 8640
  • ivermectin
    comorbidity specific
    antihelminthic
    200 mcg/kg PO × 1-2 doses (uncomplicated strongyloides) or 200 mcg/kg/d × 2 d (disseminated) • PO • single dose or 2 d
    triggers: strongyloides_screen_positive_OR_endemic_exposure_pending_serology
    MANDATORY before steroids if any strongyloides risk — steroids precipitate hyperinfection syndrome (mortality >70%); empiric coverage acceptable if serology pending
    rxcui 6069
  • albendazole
    comorbidity specific
    antihelminthic
    400 mg PO BID × 14 d (toxocara, strongyloides alternative); 400 mg PO daily × 8-30 d (hydatid) • PO • BID × 14 d
    triggers: toxocara_or_strongyloides_or_visceral_larva_migrans_confirmed
    Broad antihelminthic for parasitic EM; strongyloides alternative when ivermectin contraindicated
    rxcui 430
  • praziquantel
    comorbidity specific
    antihelminthic
    40 mg/kg PO total in 2 divided doses (schistosomiasis) • PO • split dose × 1 d
    triggers: schistosomiasis_confirmed_with_cardiac_involvement
    Schistosomiasis cardiac complications including EM-like presentation; CDC + WHO standard regimen
    rxcui 8628
  • imatinib
    first line
    tyrosine_kinase_inhibitor
    100-400 mg PO daily • PO • daily
    triggers: hes_with_fip1l1_pdgfra_fusion_positive
    CURATIVE for FIP1L1-PDGFRA+ HES — dramatic response in days (Cools NEJM 2003 PMID 12660384); preferred over steroids alone for this subset; cardiac monitoring during initiation (rare cardiogenic shock with rapid eosinophil drop in HES)
    rxcui 282388
  • mepolizumab
    first line
    anti_il_5_monoclonal_antibody
    300 mg SC q4wk (HES indication); 300 mg SC q4wk (EGPA indication) • SC • q4wk
    triggers: hes_steroid_refractory_or_pdgfra_negative, egpa_steroid_refractory_or_relapsing
    Steroid-sparing for HES (Roufosse NEJM 2008) + EGPA (MIRRA Wechsler NEJM 2017 PMID 28514601); reduces relapse + steroid burden long-term
    rxcui 1720597
  • cyclophosphamide
    comorbidity specific
    alkylating_immunosuppressant
    750 mg/m² IV monthly × 3-6 mo (EGPA induction) then maintenance with azathioprine or methotrexate • IV • monthly
    triggers: severe_egpa_with_cardiac_or_neurologic_or_renal_involvement
    EULAR/ACR 2021 + NIH protocol — induction therapy for severe EGPA with major organ involvement; cardiac is leading cause of EGPA death
    rxcui 3002
  • rituximab
    comorbidity specific
    anti_cd20_monoclonal_antibody
    375 mg/m² IV weekly × 4 doses (induction) OR 1 g IV q2wk × 2 (alternative) • IV • weekly × 4 or q2wk × 2
    triggers: egpa_alternative_to_cyclophosphamide_especially_anca_positive, fertility_preservation_concerns
    RITUXVAS / RAVE protocols for ANCA vasculitis induction; alternative to cyclophosphamide; preferred for fertility preservation
    rxcui 121191
  • furosemide
    first line
    loop_diuretic
    40-80 mg IV (diuretic-naive); 2.5x outpatient PO dose IV if on chronic loop (DOSE-trial guided) • IV • q12h titrate
    triggers: volume_overload_with_pulmonary_or_systemic_congestion
    DOSE PMID 21366472 — high-dose IV bolus or continuous infusion equivalent; titrate to UOP; transition to PO before discharge
    rxcui 4603
  • nitroglycerin
    add on
    organic_nitrate_vasodilator
    5-20 mcg/min IV titrate • IV • continuous
    triggers: hypertensive_adhf_with_sbp_above_140_and_congestion
    Preload + afterload reduction for hypertensive ADHF; AVOID if SBP <100 or RV-predominant
    rxcui 4917
  • sacubitril_valsartan
    first line
    arni_neprilysin_inhibitor_arb
    24/26 mg PO BID (titrate to 49/51 then 97/103 BID) • PO • BID
    triggers: hfref_post_em_with_ef_below_40_and_sbp_above_100
    PIONEER-HF PMID 30403955; PARADIGM-HF; 36h washout from ACEi required
    rxcui 1656328
  • carvedilol
    first line
    beta_blocker_nonselective_alpha1
    3.125 mg PO BID titrate • PO • BID
    triggers: hfref_post_em_after_inflammation_settling_or_chronic_phase
    CAPRICORN PMID 11356436 + COPERNICUS PMID 11386262; AHA 2020 myocarditis statement (PMID 32200645) caution during ACTIVE inflammation but standard initiation acceptable per most contemporary practice
    rxcui 20352
  • spironolactone
    first line
    mineralocorticoid_receptor_antagonist
    12.5-25 mg PO daily • PO • daily
    triggers: hfref_post_em_with_ef_below_35_and_k_below_5_and_egfr_above_30
    RALES PMID 10471456; monitor K + eGFR; renal dose-adjust
    rxcui 9997
  • dapagliflozin
    first line
    sglt2_inhibitor
    10 mg PO daily • PO • daily
    triggers: hfref_post_em_with_ef_below_40
    DAPA-HF PMID 31535829; 4th pillar GDMT
    rxcui 1488564
  • empagliflozin
    first line
    sglt2_inhibitor
    10 mg PO daily • PO • daily
    triggers: adhf_in_hospital_initiation_per_empulse
    EMPULSE PMID 35347356 — in-hospital initiation safe
    rxcui 1545653
  • warfarin
    comorbidity specific
    vitamin_k_antagonist
    5 mg PO daily INR target 2-3 × 3 mo for mural thrombus • PO • daily
    triggers: mural_thrombus_on_echo_in_active_em
    AHA 2022 Class IIa for LV thrombus 3-mo AC; MURAL THROMBUS very common in EM (endocardial damage prothrombotic — Loeffler endocarditis)
    rxcui 11289
  • apixaban
    comorbidity specific
    doac_factor_xa_direct
    5 mg PO BID (or 2.5 mg BID per dose-reduction criteria) • PO • BID
    triggers: mural_thrombus_warfarin_alternative, afib_post_em_with_chads_vasc_above_2
    ACC/AHA 2023 AFib (PMID 38033089) — DOAC preferred for AF; alternative for mural thrombus per smaller cohorts
    rxcui 1364430
  • amiodarone
    comorbidity specific
    class_iii_antiarrhythmic
    150 mg IV bolus then 1 mg/min × 6 h then 0.5 mg/min × 18 h • IV • continuous bolus + infusion
    triggers: sustained_vt_in_active_em, persistent_afib_with_rvr
    AHA 2020 ACLS class IIb; preferred over class I antiarrhythmics in inflamed myocardium (proarrhythmic)
    rxcui 703
  • tmp_smx_for_pcp_prophylaxis
    comorbidity specific
    antibacterial_pcp_prophylaxis
    160/800 mg PO 3×/wk or 80/400 mg daily • PO • 3×/wk or daily
    triggers: high_dose_steroids_prednisone_above_20mg_for_more_than_4wk
    PCP prophylaxis during prolonged high-dose steroid therapy; CDC + IDSA standard
    rxcui 10180

outpatient playbook — drug actions (5)

  1. 1. continue 4-pillar GDMT at maximum tolerated
    rxcui 1656328
    sacubitril-valsartan + carvedilol + spironolactone + SGLT2i at goal • PO • as scheduled
    trigger: HFrEF maintenance
    2022 ACC/AHA HF Class I
  2. 2. continue etiology-specific maintenance
    imatinib (HES) OR mepolizumab (HES/EGPA) OR azathioprine (EGPA maintenance) • PO/SC • per agent
    trigger: per etiology long-term
    Etiology-specific
  3. 3. discontinue mural thrombus AC at 3 mo if thrombus resolved
    rxcui 11289
    discontinue per repeat echo at 3 mo • PO • discontinue
    trigger: thrombus resolved on follow-up echo
    AHA 2022 Class IIa — 3 mo for mural thrombus then reassess
  4. 4. taper prednisone to discontinuation
    rxcui 8640
    taper per protocol guided by eosinophil count + clinical • PO • daily decreasing
    trigger: sustained remission
    Total 6-12 mo typical
  5. 5. maintain immunization schedule
    flu annual + COVID per CDC + pneumococcal PCV20 + recombinant zoster • IM • annual + per schedule
    trigger: post-EM maintenance
    CDC + immunocompromised guidelines

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Peripheral absolute eosinophil count >1500/µL (often >5000) + new ADHF symptoms (dyspnea, orthopnea, edema) + LV dysfunction on echo + elevated troponin → eosinophilic myocarditis until proven otherwise; Recent drug exposure (sulfa, penicillin, minocycline, clozapine, olanzapine, phenytoin, carbamazepine, lamotrigine, allopurinol) + DRESS features (fever, rash, lymphadenopathy, eosinophilia, multiorgan) + new ADHF — drug-induced eosinophilic myocarditis pathway; Asthma + sinusitis + peripheral eosinophilia + ANCA + new ADHF → EGPA (Churg-Strauss) cardiac involvement; cardiac is leading cause of death in EGPA.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Acute HF — eosinophilic myocarditis decompensation (non-shock)** (cardio.acute-hf.eosinophilic-myocarditis-decompensation.v1).
Scope: Eosinophilic myocarditis ADHF (non-shock; SCAI A-B): peripheral eosinophilia + cardiac dysfunction + STEROID RESPONSIVE; identify etiology subset (drug/DRESS, parasitic, HES with FIP1L1-PDGFRA, EGPA, idiopathic) for targeted therapy in addition to steroids; standard ADHF supportive care; STRONGYLOIDES SCREEN before steroids; AVOID NSAIDs

No severity triggers fired against current inputs.

Plan

Regimen axis: **Eosinophilic myocarditis ADHF (non-shock) — pulse methylprednisolone foundation + etiology-specific targeted therapy + standard ADHF + AC if mural thrombus + GDMT cautiously + MANDATORY strongyloides screen before steroids — ESC 2013 (PMID 23824828) + AHA 2020 (PMID 32200645) + Klion HES guidelines + MIRRA 2017 (PMID 28514601)**.
1. methylprednisolone 1 g IV daily × 3-5 d (pulse) then prednisone 1 mg/kg/d PO taper over 6-12 mo IV daily × 3-5 d then PO taper (glucocorticoid_iv_pulse, first line) — CORNERSTONE — pulse methylprednisolone for active EM; dramatic response in 24-72 h in most cases; eosinophil count drops rapidly (supports diagnosis); prednisone taper guided by eosinophil count + clinical status; ESC 2013 (PMID 23824828) + AHA 2020 (PMID 32200645)
2. prednisone 1 mg/kg/d PO daily then taper by 10 mg q2wk to 20 mg then by 5 mg/mo to 5 mg then off; total 6-12 mo PO daily (glucocorticoid_oral, first line) — Maintenance immunosuppression after pulse; titrated by eosinophil count + clinical response; prophylaxis against PCP (TMP-SMX) + steroid-induced osteoporosis (calcium + vit D ± bisphosphonate) standard
3. ivermectin 200 mcg/kg PO × 1-2 doses (uncomplicated strongyloides) or 200 mcg/kg/d × 2 d (disseminated) PO single dose or 2 d (antihelminthic, comorbidity specific) — MANDATORY before steroids if any strongyloides risk — steroids precipitate hyperinfection syndrome (mortality >70%); empiric coverage acceptable if serology pending
4. albendazole 400 mg PO BID × 14 d (toxocara, strongyloides alternative); 400 mg PO daily × 8-30 d (hydatid) PO BID × 14 d (antihelminthic, comorbidity specific) — Broad antihelminthic for parasitic EM; strongyloides alternative when ivermectin contraindicated
5. praziquantel 40 mg/kg PO total in 2 divided doses (schistosomiasis) PO split dose × 1 d (antihelminthic, comorbidity specific) — Schistosomiasis cardiac complications including EM-like presentation; CDC + WHO standard regimen
6. imatinib 100-400 mg PO daily PO daily (tyrosine_kinase_inhibitor, first line) — CURATIVE for FIP1L1-PDGFRA+ HES — dramatic response in days (Cools NEJM 2003 PMID 12660384); preferred over steroids alone for this subset; cardiac monitoring during initiation (rare cardiogenic shock with rapid eosinophil drop in HES)
7. mepolizumab 300 mg SC q4wk (HES indication); 300 mg SC q4wk (EGPA indication) SC q4wk (anti_il_5_monoclonal_antibody, first line) — Steroid-sparing for HES (Roufosse NEJM 2008) + EGPA (MIRRA Wechsler NEJM 2017 PMID 28514601); reduces relapse + steroid burden long-term
8. cyclophosphamide 750 mg/m² IV monthly × 3-6 mo (EGPA induction) then maintenance with azathioprine or methotrexate IV monthly (alkylating_immunosuppressant, comorbidity specific) — EULAR/ACR 2021 + NIH protocol — induction therapy for severe EGPA with major organ involvement; cardiac is leading cause of EGPA death
9. rituximab 375 mg/m² IV weekly × 4 doses (induction) OR 1 g IV q2wk × 2 (alternative) IV weekly × 4 or q2wk × 2 (anti_cd20_monoclonal_antibody, comorbidity specific) — RITUXVAS / RAVE protocols for ANCA vasculitis induction; alternative to cyclophosphamide; preferred for fertility preservation
10. furosemide 40-80 mg IV (diuretic-naive); 2.5x outpatient PO dose IV if on chronic loop (DOSE-trial guided) IV q12h titrate (loop_diuretic, first line) — DOSE PMID 21366472 — high-dose IV bolus or continuous infusion equivalent; titrate to UOP; transition to PO before discharge
11. nitroglycerin 5-20 mcg/min IV titrate IV continuous (organic_nitrate_vasodilator, add on) — Preload + afterload reduction for hypertensive ADHF; AVOID if SBP <100 or RV-predominant
12. sacubitril_valsartan 24/26 mg PO BID (titrate to 49/51 then 97/103 BID) PO BID (arni_neprilysin_inhibitor_arb, first line) — PIONEER-HF PMID 30403955; PARADIGM-HF; 36h washout from ACEi required
13. carvedilol 3.125 mg PO BID titrate PO BID (beta_blocker_nonselective_alpha1, first line) — CAPRICORN PMID 11356436 + COPERNICUS PMID 11386262; AHA 2020 myocarditis statement (PMID 32200645) caution during ACTIVE inflammation but standard initiation acceptable per most contemporary practice
14. spironolactone 12.5-25 mg PO daily PO daily (mineralocorticoid_receptor_antagonist, first line) — RALES PMID 10471456; monitor K + eGFR; renal dose-adjust
15. dapagliflozin 10 mg PO daily PO daily (sglt2_inhibitor, first line) — DAPA-HF PMID 31535829; 4th pillar GDMT
16. empagliflozin 10 mg PO daily PO daily (sglt2_inhibitor, first line) — EMPULSE PMID 35347356 — in-hospital initiation safe
17. warfarin 5 mg PO daily INR target 2-3 × 3 mo for mural thrombus PO daily (vitamin_k_antagonist, comorbidity specific) — AHA 2022 Class IIa for LV thrombus 3-mo AC; MURAL THROMBUS very common in EM (endocardial damage prothrombotic — Loeffler endocarditis)
18. apixaban 5 mg PO BID (or 2.5 mg BID per dose-reduction criteria) PO BID (doac_factor_xa_direct, comorbidity specific) — ACC/AHA 2023 AFib (PMID 38033089) — DOAC preferred for AF; alternative for mural thrombus per smaller cohorts
19. amiodarone 150 mg IV bolus then 1 mg/min × 6 h then 0.5 mg/min × 18 h IV continuous bolus + infusion (class_iii_antiarrhythmic, comorbidity specific) — AHA 2020 ACLS class IIb; preferred over class I antiarrhythmics in inflamed myocardium (proarrhythmic)
20. tmp_smx_for_pcp_prophylaxis 160/800 mg PO 3×/wk or 80/400 mg daily PO 3×/wk or daily (antibacterial_pcp_prophylaxis, comorbidity specific) — PCP prophylaxis during prolonged high-dose steroid therapy; CDC + IDSA standard

Setting playbook (outpatient) — Long-term cardiology + hematology/rheumatology surveillance: serial echo + cardiac MRI for recovery assessment; ICD/transplant decision at 3-6 mo if EF persistently <35; eosinophil-count-guided steroid taper to discontinuation; relapse surveillance; etiology-specific maintenance therapy; bone + metabolic health
21. continue 4-pillar GDMT at maximum tolerated sacubitril-valsartan + carvedilol + spironolactone + SGLT2i at goal PO as scheduled — HFrEF maintenance (2022 ACC/AHA HF Class I)
22. continue etiology-specific maintenance imatinib (HES) OR mepolizumab (HES/EGPA) OR azathioprine (EGPA maintenance) PO/SC per agent — per etiology long-term (Etiology-specific)
23. discontinue mural thrombus AC at 3 mo if thrombus resolved discontinue per repeat echo at 3 mo PO discontinue — thrombus resolved on follow-up echo (AHA 2022 Class IIa — 3 mo for mural thrombus then reassess)
24. taper prednisone to discontinuation taper per protocol guided by eosinophil count + clinical PO daily decreasing — sustained remission (Total 6-12 mo typical)
25. maintain immunization schedule flu annual + COVID per CDC + pneumococcal PCV20 + recombinant zoster IM annual + per schedule — post-EM maintenance (CDC + immunocompromised guidelines)

Non-pharmacologic actions:
- Cardiac rehab maintenance phase
- Activity clearance at 3-6 mo if normal echo + MRI + holter + stress test
- ICD evaluation at 3-6 mo if EF persistently <35
- Transplant referral if end-stage despite optimized therapy
- Bone health maintenance
- Family screening NOT routinely indicated (most cases sporadic)
- Monitor for steroid-related diabetes, cataracts, mood changes long-term

AVOID / contraindication checks:
- MANDATORY_strongyloides_screen_or_empiric_ivermectin_before_steroids (steroids precipitate fatal hyperinfection >70% mortality)
- Avoid_nsaids_in_active_eosinophilic_myocarditis (cardiac inflammation worsening)
- Avoid_class_i_antiarrhythmics_in_active_inflammation (proarrhythmic in inflamed myocardium)
- Steroid_pcp_prophylaxis_with_tmp_smx_for_prolonged_high_dose (prednisone >20 mg/d for >4 wk)
- Steroid_osteoporosis_prophylaxis_calcium_vit_d_bisphosphonate_for_long_courses
- Steroid_hyperglycemia_monitoring_glucose_qid_during_pulse
- Imatinib_cardiac_monitoring_during_initiation_rare_cs_with_rapid_eosinophil_drop_in_hes
- Cyclophosphamide_fertility_counseling_+_pregnancy_avoidance_+_bladder_protection_with_mesna
- Rituximab_screen_for_hbv_reactivation_+_pcp_prophylaxis
- Warfarin_avoid_active_bleeding_or_pregnancy (AHA 2022)
- Apixaban_avoid_severe_renal_impairment_egfr_below_25 (drug label)
- Amiodarone_baseline_pft_lft_tft_q6mo (pulmonary, hepatic, thyroid toxicity)
- Decision:etiology_specific_targeted_therapy_in_addition_to_steroids (FIP1L1 PDGFRA+ → imatinib; HES PDGFRA neg → mepolizumab; severe EGPA → cyclophosphamide/rituximab; parasitic → antihelminthic; DRESS → discontinue drug)
- Decision:emb_selectively_per_cooper_2007_for_definitive_diagnosis_when_etiology_unclear
- Decision:wcd_bridge_if_ef_below_35_during_recovery_window

Monitoring

Regimen monitoring:
- continuous telemetry during admission for arrhythmia surveillance
- daily weight io strict
- daily bmp for diuretic safety + steroid hyperglycemia + steroid hypokalemia
- eosinophil count daily during steroid initiation then q3 to 7d (rapid drop within 48 h supports diagnosis)
- serial troponin trend persistent elevation means ongoing injury
- echo at discharge 3 mo 6 mo for lv recovery + thrombus resolution
- cardiac mri at 3 to 6 mo for treatment response (LGE persistence prognostic)
- icd eligibility evaluation at 3 to 6 mo if ef persistently below 35
- eosinophil count at 3 + 6 + 12 mo for relapse surveillance
- inr q week during warfarin initiation for mural thrombus
- dexa scan baseline + q1y during chronic steroid therapy
- glucose qid during pulse steroids then q morning during taper
- fip1l1 pdgfra quantitative pcr q3mo during imatinib for response
- transplant referral if end stage despite optimized therapy

Setting (outpatient) monitoring:
- Quarterly cardiology + serial echo
- Cardiac MRI at 3-6 mo
- Eosinophil count q3 mo for relapse
- INR if warfarin
- Holter for arrhythmia surveillance
- DEXA q1y on chronic steroids
- Annual lipid + A1c

Follow-up plan: Cardiology at 1-2 wk + 3 + 6 + 12 mo; hematology for HES q3 mo or rheumatology for EGPA; serial echo + cardiac MRI at 3-6 mo; ICD evaluation at 3-6 mo if EF persistently <35; steroid taper guided by eosinophil count + clinical status (typically 6-12 mo total); long-term GDMT if persistent HFrEF; relapse surveillance with eosinophil count + symptoms
- Close-out criterion: long-term hematology/rheum + cardiology + steroid taper plan documented

Monitoring phase: Continuous telemetry; daily weight + I/O; daily BMP for diuresis safety + steroid hyperglycemia; eosinophil count daily during steroid initiation (rapid drop within 48 h supports response); troponin trend; echo at d/c + 3 mo + 6 mo for recovery + thrombus resolution; cardiac MRI at 3-6 mo for response; eosinophil count at 3 + 6 + 12 mo for relapse surveillance

Disposition

Current setting: outpatient — Long-term cardiology + hematology/rheumatology surveillance: serial echo + cardiac MRI for recovery assessment; ICD/transplant decision at 3-6 mo if EF persistently <35; eosinophil-count-guided steroid taper to discontinuation; relapse surveillance; etiology-specific maintenance therapy; bone + metabolic health

Disposition criteria:
- Long-term continuation; if EF normalized at 6-12 mo → consider GDMT taper trial under cardiology supervision; if persistent HFrEF → indefinite GDMT + ICD

Escalation triggers (move to higher acuity):
- Recurrent ADHF → admission
- Sustained VT → EP + ablation
- EF declining despite GDMT → advanced HF eval + transplant
- Eosinophil count rising on taper → relapse → re-escalate immunosuppression or add mepolizumab
- New systemic features → reassess for EGPA flare or HES progression

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Hemodynamic deterioration to SCAI C+ shock (SBP <90 + lactate ≥2 + cool extremities + organ dysfunction) — fulminant EM requires MCS evaluation + emergent EMB
- [LIFE_THREATENING] Patient about to receive steroids without strongyloides screen completed AND endemic exposure history (Latin America, sub-Saharan Africa, SE Asia, immigration, travel) — life-threatening hyperinfection risk if not pre-treated
- [LIFE_THREATENING] Mural thrombus identified on echo (very common in EM — endocardial damage prothrombotic — Loeffler endocarditis) + systemic embolic event (stroke, peripheral arterial embolism, mesenteric, renal)

Citations

- ESC 2013 myocarditis position statement (Caforio PMID 23824828) + AHA 2020 myocarditis scientific statement (Tschöpe PMID 32200645) + 2022 ACC/AHA HF Guideline (Heidenreich PMID 35363499) + Klion HES treatment guidelines + MIRRA EGPA (Wechsler NEJM 2017 PMID 28514601) [PMID:23824828](https://pubmed.ncbi.nlm.nih.gov/23824828/)
- Cited evidence (PMID 32200645) [PMID:32200645](https://pubmed.ncbi.nlm.nih.gov/32200645/)
- Cited evidence (PMID 35363499) [PMID:35363499](https://pubmed.ncbi.nlm.nih.gov/35363499/)
- Cited evidence (PMID 30217631) [PMID:30217631](https://pubmed.ncbi.nlm.nih.gov/30217631/)
- Cited evidence (PMID 30290974) [PMID:30290974](https://pubmed.ncbi.nlm.nih.gov/30290974/)

Last reconciled with current guidelines: 2026-05-15.
References
  • ESC 2013 myocarditis position statement (Caforio PMID 23824828) + AHA 2020 myocarditis scientific statement (Tschöpe PMID 32200645) + 2022 ACC/AHA HF Guideline (Heidenreich PMID 35363499) + Klion HES treatment guidelines + MIRRA EGPA (Wechsler NEJM 2017 PMID 28514601) — PMID:23824828
  • Cited evidence (PMID 32200645) — PMID:32200645
  • Cited evidence (PMID 35363499) — PMID:35363499
  • Cited evidence (PMID 30217631) — PMID:30217631
  • Cited evidence (PMID 30290974) — PMID:30290974